Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies by Seini Moimoi | Aug 25, 2022 | Portfolio News
89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASH by Seini Moimoi | Aug 18, 2022 | Portfolio News
Cohere Health’s UM Platform Earns HITRUST r2 Certification by Seini Moimoi | Aug 17, 2022 | Portfolio News
Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio by Seini Moimoi | Aug 17, 2022 | Portfolio News
Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates by Seini Moimoi | Aug 15, 2022 | Portfolio News
Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update by Seini Moimoi | Aug 15, 2022 | Portfolio News
Tricida Announces Second Quarter 2022 Financial Results by Seini Moimoi | Aug 13, 2022 | Portfolio News
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia by Seini Moimoi | Aug 12, 2022 | Portfolio News
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 by Seini Moimoi | Aug 11, 2022 | Portfolio News
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis by Seini Moimoi | Aug 11, 2022 | Portfolio News
